Quantification and time course of subjective psychotropic and somatic effects of tetrahydrocannabinol - a prospective, single-blind, placebo-controlled exploratory trial in healthy volunteers

• Published in: BMC psychiatry 2024-12, Vol.24 (1), p.902-11, Article 902
• Main Authors: Kleine-Brueggeney, Maren, Huber, Markus, Theiler, Lorenz, Priemer, Fritz, Greif, Robert
• Format: Article
• Language: English
• Subjects: Adult; Affect - drug effects; Blood pressure; Cannabis; Cytochrome; Dronabinol - administration & dosage; Dronabinol - adverse effects; Dronabinol - blood; Dronabinol - pharmacology; Female; Health care; Healthy Volunteers; Hospitals; Humans; Irritation; Male; Marijuana; Metabolites; Mood; Pharmacokinetics; Placebos; Plasma levels; Prospective Studies; Psychotropic Drugs - adverse effects; Psychotropic effects; Questionnaires; Single-Blind Method; Sleep and wakefulness; Somatic effects; Statistical analysis; Tetrahydrocannabinol; THC; Time Factors; Young Adult
• ISSN: 1471-244X; 1471-244X
• DOI: 10.1186/s12888-024-06338-2

Cannabis is increasingly used and debates about the legalisation of the recreational use of cannabis are ongoing. In this prospective, placebo-controlled study in healthy volunteers not regularly consuming cannabis, subjective psychotropic and somatic effects after a single dose of intravenous THC were assessed and quantified over 48 h. Twenty-five healthy volunteers received a single IV bolus of THC and 6 received normal saline. Psychotropic and somatic effects of THC were assessed by two questionnaires that were completed at up to 14 timepoints from shortly before drug administration to 48 h later. Demographic data did not differ between groups. Differences between THC and placebo for all assessed effects, except for euphoria, irritation and headache, were clearly discernible. Subdimensions related to positive mood were less and those related to negative mood were more pronounced in the THC group. Peak plasma concentrations were observed at 1 to 5 min after THC administration while peak effects occurred between 45 and 60 min. Differences between THC and placebo were pronounced and seen for up to 90 to 120 min for most effects, except for "sleepiness" and "deactivation", where the effect of THC was discernible for up to 5 h. At 24 and 48 h, there were no statistically significant difference between THC and placebo group. THC triggers a large range of psychotropic and somatic effects with peak effects at 45 to 60 min after IV administration of THC, much later than plasma peak levels. Most effects are short-lasting with a duration of up to 2 h, but some effects like sleepiness and deactivation can be longer-lasting and persist for 5 h or longer in cannabis-naïve or cannabis-abstinent individuals. Since effects of THC demonstrate a time course that differs from the time course of plasma concentrations it might be important to base the judgment of a possible impairment related to THC consumption on clinical or behavioral tests in addition to THC plasma levels. www.isrctn.com ; registration number ISRCTN53019164.